<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/990FEC22-C988-4943-AA62-01322D61942A"><gtr:id>990FEC22-C988-4943-AA62-01322D61942A</gtr:id><gtr:name>Medicines for Malaria Venture (MMV)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ACB5DBCD-F829-402F-AE06-8E61E5EB71D4"><gtr:id>ACB5DBCD-F829-402F-AE06-8E61E5EB71D4</gtr:id><gtr:name>Worldwide Antimalarial Resistance Networkn WWARN</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E27575EF-ABFB-484B-BEEF-53343150A49E"><gtr:id>E27575EF-ABFB-484B-BEEF-53343150A49E</gtr:id><gtr:name>Bill and Melinda Gates Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/734F19C1-61E5-45B1-A183-63FDD145328F"><gtr:id>734F19C1-61E5-45B1-A183-63FDD145328F</gtr:id><gtr:name>World Health Organization (WHO)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>School of Public Health</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/990FEC22-C988-4943-AA62-01322D61942A"><gtr:id>990FEC22-C988-4943-AA62-01322D61942A</gtr:id><gtr:name>Medicines for Malaria Venture (MMV)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACB5DBCD-F829-402F-AE06-8E61E5EB71D4"><gtr:id>ACB5DBCD-F829-402F-AE06-8E61E5EB71D4</gtr:id><gtr:name>Worldwide Antimalarial Resistance Networkn WWARN</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E27575EF-ABFB-484B-BEEF-53343150A49E"><gtr:id>E27575EF-ABFB-484B-BEEF-53343150A49E</gtr:id><gtr:name>Bill and Melinda Gates Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/734F19C1-61E5-45B1-A183-63FDD145328F"><gtr:id>734F19C1-61E5-45B1-A183-63FDD145328F</gtr:id><gtr:name>World Health Organization (WHO)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3945FED2-640B-4AE5-9097-02C66212286C"><gtr:id>3945FED2-640B-4AE5-9097-02C66212286C</gtr:id><gtr:firstName>Lucy</gtr:firstName><gtr:surname>Okell</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002387"><gtr:id>EF455315-7451-402D-8721-BC9AD0F65D2F</gtr:id><gtr:title>Spatio-temporal dynamics of drug-resistant Plasmodium falciparum malaria in Africa: implications for public health</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1002387</gtr:grantReference><gtr:abstractText>Malaria is a parasite which can cause severe illness and death in humans if they do not receive effective treatment. In the 1990s, parasites resistant to malaria drugs spread from Asia throughout the African continent, causing mortality from the disease to double or triple in many areas. New, effective artemisinin therapies are now used across the world. However, recently parasites in South-East Asia have developed resistance to these new treatments and are highly likely to spread to Africa once again. 

Dr Okell, a researcher based in the Department of Infectious Disease Epidemiology at Imperial College London, will develop a computer simulation to describe how resistant strains spread across Africa over time, based on extensive analysis of historical data on resistance. Through understanding what factors contributed towards or prevented the spread of drug resistance in the past, the research will identify which control strategies could be the most effective against the new resistant parasites. For example, national control programs could improve the accuracy of diagnosis to reduce the overuse of treatment, or introduce better transmission control. As more than 80% of global malaria cases (200 million) occur in Africa, successful control of drug resistance will have a huge public health impact.</gtr:abstractText><gtr:technicalSummary>Background

In the 1990s, the spread of drug-resistant Plasmodium falciparum malaria strains in Africa after importation from South-East Asia led to a substantial increase in malaria mortality. New first-line antimalarial treatments, artemisinin combination therapies (ACTs), are currently efficacious in Africa but artemisinin-resistant strains have recently emerged in South-East Asia. Artemisinin resistance is likely to spread to Africa where more than 80% of global malaria cases currently occur. Given the lack of affordable alternative antimalarials, understanding how resistance spreads in Africa and how it can be contained is a key public health question. An important first step is to characterize the spread of resistance to sulphadoxine-pyrimethamine (SP), the previous first line treatment. Molecular analysis has made it possible to measure the spread of parasite lineages resistant to SP across Africa over time. Mathematical models are powerful tools for analysis of such data. The aim of this project is to use models to identify causal factors behind the pattern of SP resistance spread, indicate likely dispersal routes of artemisinin resistance for monitoring purposes and compare proposed control strategies. 



Proposed work

The first objective of this project is to develop a spatially-structured transmission model to describe the spread of SP-resistant genotypes over time across Africa. Factors likely to determine the rate of spread of a resistant strain will be incorporated, including the usage of the antimalarial, the level of transmission intensity, the evolutionary fitness of the resistant strain relative to competing wild-types, and pharmacokinetics of the drug. Available administrative area-level data on antimalarial use and transmission intensity will be used in a metapopulation model framework. Furthermore the role of human travel in transferring resistant strains from Asia to Africa and between areas within Africa will be investigated using gravity models and migration data. The model will be calibrated against geo-referenced data on the prevalence of SP resistance mutations. The next main objective is to adapt the fully-developed model to characterize the potential spatio-temporal spread of artemisinin-resistant parasites under different scenarios and identify key countries at risk where artemisinin resistance should be monitored. Proposed policies to contain this spread will be modelled and contrasted, including vector control, preventing overuse of treatment, introducing multiple first-line therapies and preventing artemisinin monotherapy use. Such models could be key to informing policy given the public health urgency and lack of resources to empirically test the full range of control options across different endemic areas.</gtr:technicalSummary><gtr:fund><gtr:end>2015-08-08</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-09-26</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>305801</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Worldwide Antimalarial Resistance Networkn WWARN</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>WWARN</gtr:description><gtr:id>231DAB8F-12E2-4C49-8C0E-2D008951D71F</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>neXgDV1iyZP-1</gtr:outcomeId><gtr:partnerContribution>WWARN contributed data and guidance.</gtr:partnerContribution><gtr:piContribution>We set up a study group in 2013 in collaboration with WWARN to conduct an analysis on the prophylactic protection given by the antimalarial amodiaquine.

In 2016 we set up a further study group with WWARN to conduct analysis of multiple clinical trials of the antimalarial mefloquine.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medicines for Malaria Venture (MMV)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Medicines for Malaria Venture</gtr:description><gtr:id>E466111E-956B-4232-8EC7-1395ABD65662</gtr:id><gtr:impact>Presentation at MMV meeting in Geneva
Symposium at ASTMH 2012, Atlanta, showing initial results.
Full report to MMV: Modelling to maximize the benefits of ACTs: Final report to Medicines for Malaria Venture. July 2013
Publication in Nature communications PMID 25425081.</gtr:impact><gtr:outcomeId>kGwbhLvDEmj-1</gtr:outcomeId><gtr:partnerContribution>Advice on project, funding travel to meetings.</gtr:partnerContribution><gtr:piContribution>Analysis of data and modelling to estimate impact of post-treatment prophylaxis by the new antimalarial DHA-piperaquine.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust</gtr:collaboratingOrganisation><gtr:country>Malawi, Republic of</gtr:country><gtr:department>Malawi-Liverpool Wellcome Trust Clinical Research Programme</gtr:department><gtr:description>Malawi/Kenya</gtr:description><gtr:id>BBF9F837-9C2F-49A8-8E8D-FDF3E7B76FB6</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>589c9e650e40c4.02953150-1</gtr:outcomeId><gtr:partnerContribution>The partner will host our postdoc for a number of months in Malawi, provide supervision, regular phone calls to discuss the progress of the project. They are also currently undertaking large trials of intermittent preventive treatment in pregnant women, and these trials will help to inform our modelling analysis.</gtr:partnerContribution><gtr:piContribution>I will recruit a postdoc to undertake modelling of the impact of intermittent treatment in pregnancy for malaria on drug resistance development. We will also contribute to capacity building of mathematical modelling in the Malawi Programme.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>World Health Organization (WHO)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>WHO</gtr:description><gtr:id>C84C238D-93DF-4BD8-B9F2-D21208D8B8AF</gtr:id><gtr:impact>A report to the World Health Organization: Assessing the impact of artemisinin resistance in Sub-Saharan Africa: Final report to the World Health Organization. December 2013</gtr:impact><gtr:outcomeId>N4NWi8AAjZG-1</gtr:outcomeId><gtr:partnerContribution>Funding and overview, advice on research approach</gtr:partnerContribution><gtr:piContribution>Supervision of a postdoctoral researcher to work on analysis of the impact of artemisinin resistance in Africa.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Sanofi data collaboration</gtr:description><gtr:id>0F38BF3F-AF49-4D11-BB91-13174EBCF218</gtr:id><gtr:impact>Publication draft in progress.</gtr:impact><gtr:outcomeId>56df479878f1f5.15602338-1</gtr:outcomeId><gtr:partnerContribution>They contributed data.</gtr:partnerContribution><gtr:piContribution>We have carried out secondary analysis of trial data, to estimate the post-treatment prophylactic effect of artesunate amodiaquine.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>START-IPT study collaborator</gtr:description><gtr:id>C03811AD-B328-4220-9EC9-1E2BF05241B7</gtr:id><gtr:impact>Informed trial design. The collaboration is multi disciplinary, including mathematical modellers, clinicians, epidemiologists.</gtr:impact><gtr:outcomeId>54636b55764ef2.86866778-1</gtr:outcomeId><gtr:partnerContribution>Design and carrying out a cluster-randomized trial of Intermittent Preventive Treatment for malaria in school children in Uganda.</gtr:partnerContribution><gtr:piContribution>We have produced models of Intermittent Preventive Treatment for malaria in school children, to assist the design of a trial and give an estimate of likely effect.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bill and Melinda Gates Foundation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Member of Malaria Modelling Consortium</gtr:description><gtr:id>899895DC-E33C-4E12-AB31-47ACE6D4E807</gtr:id><gtr:impact>Malaria Modelling Consortium report to the World Health Organization Malaria Policy Advisory Group on results from modelling mass drug administration for malaria control</gtr:impact><gtr:outcomeId>55d34d4d5fddd8.62052268-1</gtr:outcomeId><gtr:partnerContribution>Other modelling partners contribute modelling results, the Gates Foundation coordinate activities, arrange meetings and fund travel for the meetings.</gtr:partnerContribution><gtr:piContribution>I participated in consortium meetings, and contributed substantially to a Malaria Modelling Consortium report to the World Health Organization Malaria Policy Advisory Group on results from modelling mass drug administration for malaria control.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medicines for Malaria Venture (MMV)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Medicines for Malaria Venture</gtr:description><gtr:id>AB46BB98-2C67-49D3-A888-347F39D72E81</gtr:id><gtr:impact>A data collaboration with the Worldwide Antimalarial Resistance Network and Sanofi Ltd to access clinical trial data.</gtr:impact><gtr:outcomeId>5462325bdf2b05.14495889-1</gtr:outcomeId><gtr:partnerContribution>Funding (research costs and 1 postdoc for 3 years), requests for research and advice on ongoing work.</gtr:partnerContribution><gtr:piContribution>We are using mathematical modelling to estimate the impact of both existing antimalarial drugs and also products in development on malaria transmission, and their cost-effectiveness.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bill and Melinda Gates Foundation</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Diagnostics Modelling Consortium</gtr:department><gtr:description>Member of Diagnostics Modelling Consortium</gtr:description><gtr:id>5084BDC0-B0E0-4A10-82A6-865F1C061D54</gtr:id><gtr:impact>Publication: Comparison of diagnostics for the detection of asymptomatic Plasmodium falciparum infections to inform control and elimination strategies.
Wu L, van den Hoogen LL, Slater H, Walker PG, Ghani AC, Drakeley CJ, Okell LC.
Nature. 2015 Dec 3;528(7580):S86-93. doi: 10.1038/nature16039.</gtr:impact><gtr:outcomeId>546322e1d06835.34682937-1</gtr:outcomeId><gtr:partnerContribution>Overview and deciding research questions, as well as giving feedback on research underway by the consortium members.</gtr:partnerContribution><gtr:piContribution>I am a member of this consortium funded by the Bill &amp;amp; Melinda Gates Foundation, working on identifying target product profiles for a malaria diagnostics with different uses. I am helping to supervise two students on a project to systematically review and compare diagnostic techniques. I attend meetings and give feedback on work done by others in the consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>483615</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Society Dorothy Hodgkin Fellowship</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>76B3726A-4BA8-4CD3-B419-5DC2326B9B23</gtr:id><gtr:outcomeId>55d35105178877.84623396</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99998</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Challenge Grant</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>BB6AB1C7-64FE-4AAE-96F0-1FE087578CB0</gtr:id><gtr:outcomeId>589c9d3d0f47c7.71831982</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in World Health Organization policy document</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>C185CEBD-5EC5-44F6-A4D4-8D28A8815E79</gtr:id><gtr:impact>Increased use of sensitive malaria diagnostics which increase the number of infections detected and therefore increase treatment rates, reduce transmission, and help to give a better understanding of the true burden of malaria.</gtr:impact><gtr:outcomeId>546326a008f0a0.42050321</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://www.who.int/malaria/publications/atoz/policy-brief-diagnosis-low-transmission-settings/en/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>PATH Technical Advisory Group</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>1C329891-4434-43C5-927B-FE989F52010D</gtr:id><gtr:outcomeId>r9R5aT4sL4n</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type><gtr:url>http://sites.path.org/dx/malaria/malaria-elimination/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invited talk at Bill &amp;amp;Melinda Gates Foundation, Modeling the Impact of Diagnostics in Global Health Convening Meeting, Seattle: The sensitivity of malaria microscopy</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>3B481A1A-1078-44CF-A215-3E5927ADF709</gtr:id><gtr:outcomeId>54636964b40189.10912086</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in Lancet review</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>3C2A76DE-5105-47C7-8B74-ACF04D813789</gtr:id><gtr:outcomeId>nPhhQZYUJA2</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type><gtr:url>http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60310-4/abstract</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Presentation at Medicines for Malaria Venture, Geneva</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>F93FCB84-CA97-4479-AE17-43F137B84781</gtr:id><gtr:outcomeId>Cnrv1gZnKNd</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invited talk, Modeling to Support Decision Making Meeting, Bill &amp;amp; Melinda Gates Foundation, Seattle: Estimating the impact of dihydroartemisinin-piperaquine on malaria transmission.</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>950B0A0E-363B-4A54-9A9A-128F2D250673</gtr:id><gtr:outcomeId>546369c1010614.57857718</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Report for the World Health Organization Malaria Policy Advisory Committee</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>AB4B93AF-2369-4CCF-BBC1-24E82976D81A</gtr:id><gtr:outcomeId>55d3518884b357.29340114</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in Trends in Parasitology Review</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>81B0C988-2ABC-4DA5-A42C-EBA0250F4310</gtr:id><gtr:outcomeId>54636536c66195.69209412</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type><gtr:url>http://www.sciencedirect.com/science/article/pii/S1471492214000336</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in World Health Organization policy document</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>2CF30509-18E1-4441-AB34-F35426C49ACB</gtr:id><gtr:impact>Increased use of sensitive malaria diagnostics which increase the number of infections detected and therefore increase treatment rates, reduce transmission, and help to give a better understanding of the true burden of malaria.</gtr:impact><gtr:outcomeId>546327202655b8.02536090</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://www.who.int/malaria/publications/atoz/policy-brief-diagnosis-low-transmission-settings/en/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO molecular diagnostics evidence review</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B00A0835-55C6-4D89-8CCE-A618387F7A08</gtr:id><gtr:impact>Increased use of sensitive malaria diagnostics which increase the number of infections detected and therefore increase treatment rates, reduce transmission, and help to give a better understanding of the true burden of malaria.</gtr:impact><gtr:outcomeId>DEpkGn9u8QK</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in World Health Organization policy document</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B8FCBB60-1805-409F-8F92-2B7FFDFB2D76</gtr:id><gtr:impact>Increased use of sensitive malaria diagnostics which increase the number of infections detected and therefore increase treatment rates, reduce transmission, and help to give a better understanding of the true burden of malaria.</gtr:impact><gtr:outcomeId>5463271fede850.67993672</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://www.who.int/malaria/publications/atoz/policy-brief-diagnosis-low-transmission-settings/en/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Based on a systematic review, we provided a spreadsheet tool to estimate malaria prevalence, converting between microscopy and PCR measures. This was provided as a supplement in an Open Access online publication.</gtr:description><gtr:id>F577EC6B-2BE4-4C87-AB67-F1454D105C71</gtr:id><gtr:impact>Other research groups are using this model to estimate malaria prevalence.</gtr:impact><gtr:outcomeId>546377a36a5898.65548318</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Model to estimate malaria prevalence</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:url>http://www.nature.com/ncomms/journal/v3/n12/abs/ncomms2241.html#supplementary-information</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>This contains the results of a quantitative review of malaria diagnostic methods when used in asymptomatic populations (rapid diagnostic tests, PCR, microscopy). Published as a spreadsheet supplement to the publication detailed below.</gtr:description><gtr:id>70D4FAE4-B30F-48EB-A45C-EAFCE8E9AB50</gtr:id><gtr:impact>None yet (published Dec 2015)</gtr:impact><gtr:outcomeId>56df48b8b3b013.13789058</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>RDT-PCR-microscopy systematic review</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.nature.com/nature/journal/v528/n7580_supp_custom/full/nature16039.html</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Database from a systematic review of the prevalence of malaria when measured by different diagnostic techniques: PCR versus microscopy, and other characteristics of studies. The raw data were made available online as part of a publication PMID 23212366</gtr:description><gtr:id>6AD1DCE9-AB71-4B24-B164-A2ED4C82B792</gtr:id><gtr:impact>The World Health Organization requested a more detailed version of the raw data.</gtr:impact><gtr:outcomeId>55d355004434a4.68452886</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PCR &amp; microscopy prevalence systematic review</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.nature.com/ncomms/journal/v3/n12/full/ncomms2241.html</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7E98FBD2-D044-49CD-808C-3360E8ED5FFE</gtr:id><gtr:title>Going below the tip of the iceberg: does molecular detection of malaria change our understanding of epidemiology and control? (oral presentation)</gtr:title><gtr:parentPublicationTitle>American Journal of Tropical Medicine &amp; Hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b937ad1e545c9b96eb4acdc78ebd6c6"><gtr:id>3b937ad1e545c9b96eb4acdc78ebd6c6</gtr:id><gtr:otherNames>Lucy Okell</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>KcsTnEHGDaN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC01290D-8D2F-4526-84ED-DF7A61C591BC</gtr:id><gtr:title>The role of antimalarial treatment in the elimination of malaria.</gtr:title><gtr:parentPublicationTitle>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de12a795df274d5a8299b86b9351390d"><gtr:id>de12a795df274d5a8299b86b9351390d</gtr:id><gtr:otherNames>Gosling RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1198-743X</gtr:issn><gtr:outcomeId>pm_14579_29_21951597</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62BD230D-7A5B-4AEC-9945-68294C4A67CC</gtr:id><gtr:title>The essential role of infection-detection technologies for malaria elimination and eradication.</gtr:title><gtr:parentPublicationTitle>Trends in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c8558ce1888b1dd78e9c0a60f3f02ea"><gtr:id>7c8558ce1888b1dd78e9c0a60f3f02ea</gtr:id><gtr:otherNames>Tietje K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-4922</gtr:issn><gtr:outcomeId>54622b2f9e75d2.44545999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14793020-B18E-4319-8BF3-2720658A33C6</gtr:id><gtr:title>From intervention to impact: modelling the potential mortality impact achievable by different LLIN delivery strategies (oral presentation)</gtr:title><gtr:parentPublicationTitle>American Journal of Tropical Medicine &amp; Hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b937ad1e545c9b96eb4acdc78ebd6c6"><gtr:id>3b937ad1e545c9b96eb4acdc78ebd6c6</gtr:id><gtr:otherNames>Lucy Okell</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>eoikpywLfVo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4929C233-54B5-47B4-909D-CEE2C04C49DB</gtr:id><gtr:title>Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f24279cb762cddc202acc37d8f569f7"><gtr:id>4f24279cb762cddc202acc37d8f569f7</gtr:id><gtr:otherNames>Okell LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>54622bdbefa488.10237235</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3D5184F-85E2-47DC-8AA8-5AE93941E5BC</gtr:id><gtr:title>Estimating the protective effects of dihydroartemisinin-piperaquine against P. falciparum malaria</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f24279cb762cddc202acc37d8f569f7"><gtr:id>4f24279cb762cddc202acc37d8f569f7</gtr:id><gtr:otherNames>Okell LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>54622dd6f26c31.49557583</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64112C6F-8C6D-45ED-A804-144633FA14A3</gtr:id><gtr:title>The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/730ae9ad8c71b39ddf56c92de27a5308"><gtr:id>730ae9ad8c71b39ddf56c92de27a5308</gtr:id><gtr:otherNames>Slater HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>54622b2f7a2ab3.24815262</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64405717-5B07-439F-820F-C2F8003C7C50</gtr:id><gtr:title>Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0242d6d1156507f390e16a3eddb937bf"><gtr:id>0242d6d1156507f390e16a3eddb937bf</gtr:id><gtr:otherNames>Beshir KB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_14579_29_23945376</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD0EBABD-9C1E-4EAE-A84E-68658187EC23</gtr:id><gtr:title>Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Global health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fe8e8fc70388bea4799104ce592f8d2"><gtr:id>0fe8e8fc70388bea4799104ce592f8d2</gtr:id><gtr:otherNames>Brady OJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2214-109X</gtr:issn><gtr:outcomeId>5a578bb49ea8a4.75172684</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>650B9817-0068-4A5A-B6B4-4CF4F3E06875</gtr:id><gtr:title>Seasonality in malaria transmission: implications for case-management with long-acting artemisinin combination therapy in sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f51342f6c7c83db2e5ba87a366a48f4a"><gtr:id>f51342f6c7c83db2e5ba87a366a48f4a</gtr:id><gtr:otherNames>Cairns ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>55d34b08bd4251.62165462</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E491D7E-2B69-4F68-B136-7785BB68D5B4</gtr:id><gtr:title>Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f24279cb762cddc202acc37d8f569f7"><gtr:id>4f24279cb762cddc202acc37d8f569f7</gtr:id><gtr:otherNames>Okell LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa28fda50c012.71094390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86A64A8D-ACB5-4D56-B351-1E3719F9B847</gtr:id><gtr:title>Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/730ae9ad8c71b39ddf56c92de27a5308"><gtr:id>730ae9ad8c71b39ddf56c92de27a5308</gtr:id><gtr:otherNames>Slater HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>56df46a05e23d4.56822503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3C5D34C-3C23-42AB-B73C-5C97B34183D3</gtr:id><gtr:title>Estimating the protective effects of a long-acting antimalarial, dihydroartemisinin-piperaquine, against P. falciparum malaria (poster presentation)</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b937ad1e545c9b96eb4acdc78ebd6c6"><gtr:id>3b937ad1e545c9b96eb4acdc78ebd6c6</gtr:id><gtr:otherNames>Lucy Okell</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>g442aWLC6yh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E10503F-DF24-4EBF-97B0-54A53813409C</gtr:id><gtr:title>Factors determining the occurrence of submicroscopic malaria infections and their relevance for control.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f24279cb762cddc202acc37d8f569f7"><gtr:id>4f24279cb762cddc202acc37d8f569f7</gtr:id><gtr:otherNames>Okell LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>egsrTvjoBkF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BEE72044-B093-4BBA-B4E4-0253943BF04A</gtr:id><gtr:title>Asymptomatic malaria infections: detectability, transmissibility and public health relevance.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/257135c67b585b044c8c4d0cf4577d5b"><gtr:id>257135c67b585b044c8c4d0cf4577d5b</gtr:id><gtr:otherNames>Bousema T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1740-1526</gtr:issn><gtr:outcomeId>54622b2f5544d6.30121609</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4A8EA2B-80AA-4F8E-AF0F-B2B0107873E2</gtr:id><gtr:title>Association of sub-microscopic malaria parasite carriage with transmission intensity in north-eastern Tanzania.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04b51454b7779504ab271ad8bae5b911"><gtr:id>04b51454b7779504ab271ad8bae5b911</gtr:id><gtr:otherNames>Manjurano A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>pm_14579_29_22177014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E13088C0-38AF-4C8E-A207-E9897ECC8528</gtr:id><gtr:title>Understanding the historical spread of molecular markers of sulphadoxine-pyrimethamine resistance in Africa</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2d53ef7ab5ef291071a9a2b02c161d5"><gtr:id>d2d53ef7ab5ef291071a9a2b02c161d5</gtr:id><gtr:otherNames>LC Okell</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>55d3527218f836.17556159</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEDE4CB6-03C6-4626-A5B4-3200B41FBBD3</gtr:id><gtr:title>From intervention to impact: modelling the potential mortality impact achievable by different long-lasting, insecticide-treated net delivery strategies.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f24279cb762cddc202acc37d8f569f7"><gtr:id>4f24279cb762cddc202acc37d8f569f7</gtr:id><gtr:otherNames>Okell LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>pm_14579_29_22974140</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>133CC0EC-E3F5-41C8-9852-5395A456DFDD</gtr:id><gtr:title>Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07dfabc74b6b6824d6b3ac8d5c7a6063"><gtr:id>07dfabc74b6b6824d6b3ac8d5c7a6063</gtr:id><gtr:otherNames>Sawa P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_14579_29_23468056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4D508D8-162E-4468-B94B-5049E7749226</gtr:id><gtr:title>Mathematical Modelling to Guide Drug Development for Malaria Elimination.</gtr:title><gtr:parentPublicationTitle>Trends in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/730ae9ad8c71b39ddf56c92de27a5308"><gtr:id>730ae9ad8c71b39ddf56c92de27a5308</gtr:id><gtr:otherNames>Slater HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-4922</gtr:issn><gtr:outcomeId>585d5a19c93a47.83099630</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88D887B5-0E8D-461A-9559-9200915158B4</gtr:id><gtr:title>Factors influencing the infectivity of asymptomatic human infections to anophelines</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f24279cb762cddc202acc37d8f569f7"><gtr:id>4f24279cb762cddc202acc37d8f569f7</gtr:id><gtr:otherNames>Okell LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>54622f799b9ea5.90046230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00E49625-405A-42E2-A671-05A1D85E4B37</gtr:id><gtr:title>Comparison of diagnostics for the detection of asymptomatic Plasmodium falciparum infections to inform control and elimination strategies.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/688c724f0634d353269671f0a3751196"><gtr:id>688c724f0634d353269671f0a3751196</gtr:id><gtr:otherNames>Wu L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>56df46a0832bd2.46891498</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63A23D0D-0D96-4FEB-9EE8-AAC5651340CF</gtr:id><gtr:title>Modelling the benefits of long-acting or transmission-blocking drugs for reducing Plasmodium falciparum transmission by case management or by mass treatment.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e923169097ec6549bab84a5a9a3d64cb"><gtr:id>e923169097ec6549bab84a5a9a3d64cb</gtr:id><gtr:otherNames>Bretscher MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>5aa28fda7a9208.40781944</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002387</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>FB395309-E202-4FE8-87B0-041A3D72D4D4</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.5  Research design and methodologies (aetiology)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>